Details
Stereochemistry | ACHIRAL |
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Mg]
InChI
InChIKey=RSHAOIXHUHAZPM-UHFFFAOYSA-N
InChI=1S/Mg.2H
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure. | 1977 |
|
[Magnesium--an alternative in treatment resistant tachyarrhythmias]. | 1977 May 30 |
|
Regulation of membrane histamine H1-receptor binding sites by guanine nucleotides, mono- and divalent cations. | 1986 Apr |
|
Decreased intracellular free magnesium in erythrocytes of spontaneously hypertensive rats. | 1987 Mar 30 |
|
Polylysine specifically activates the insulin-dependent insulin receptor protein kinase. | 1989 Jun 15 |
|
Cocaine-induced cerebral vascular damage can be ameliorated by Mg2+ in rat brain. | 1990 Feb 5 |
|
Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidine. | 1990 May |
|
Persistent paralysis in critically ill patients after long-term administration of vecuronium. | 1992 Aug 20 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Familial hypomagnesemia--hypercalciuria and pseudotumor cerebri. | 2001 |
|
Complement activation in factor D-deficient mice. | 2001 Dec 4 |
|
Evidence supporting a role for KCl cotransporter in the thick ascending limb of Henle's loop. | 2001 Nov |
|
Polyvalent cation-sensing mechanism increased Na(+)-independent Mg(2+) transport in renal epithelial cells. | 2001 Sep 28 |
|
Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed. | 2002 Jul |
|
Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. | 2002 Nov |
|
Vasodilator agents protect against indinavir nephrotoxicity. | 2003 Aug |
|
Cell-associated magnesium and QT dispersion in hemodialysis patients. | 2003 Jan |
|
Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. | 2003 Nov |
|
Elevated levels of ferrimagnetic metals in foodchains supporting the Guam cluster of neurodegeneration: do metal nucleated crystal contaminants [corrected] evoke magnetic fields that initiate the progressive pathogenesis of neurodegeneration? | 2004 |
|
The effect of cations on the amidase activity of human tissue kallikrein: 1-linear competitive inhibition by sodium, potassium, calcium and magnesium. 2-linear mixed inhibition by aluminium. | 2004 Aug |
|
Ablation of calcitonin/calcitonin gene-related peptide-alpha impairs fetal magnesium but not calcium homeostasis. | 2004 Aug |
|
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. | 2004 Aug 18 |
|
Low maternal dietary intakes of iron, magnesium, and niacin are associated with spina bifida in the offspring. | 2004 Jun |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
A novel cation-sensing mechanism in osteoblasts is a molecular target for strontium. | 2004 May |
|
In vitro application of endotoxin to thoracic aortas from magnesium-deficient rats enhances vascular hyporeactivity to phenylephrine. | 2004 Oct |
|
Major and trace elements in whole blood of phlebotomized patients with porphyria cutanea tarda. | 2005 |
|
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. | 2005 Oct |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Further characterization of mammalian ceramide kinase: substrate delivery and (stereo)specificity, tissue distribution, and subcellular localization studies. | 2006 Feb |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
Evidence for a two-step mechanism involved in the formation of covalent HC x TSG-6 complexes. | 2006 Jun 20 |
|
Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. | 2006 Mar |
|
Uncompetitive inhibition of Xenopus laevis aldehyde dehydrogenase 1A1 by divalent cations. | 2006 Mar |
|
The expression of genes for transepithelial calcium-transporting proteins in the bovine duodenum. | 2006 Mar |
|
Divalent-metal-dependent nucleolytic activity of Cu, Zn superoxide dismutase. | 2006 Oct |
|
[The characterization of central neuromediation in rats fed with magnesium-deprived diet before and after magnesium replenishment]. | 2008 Jul |
|
Treatment of migraine with prophylactic drugs. | 2008 Oct |
|
Cocaine use disorders and serum magnesium profile. | 2009 |
|
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation. | 2009 Jun 23 |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin. | 2011 Jul-Aug |
|
Hypoxia induces an increase in intracellular magnesium via transient receptor potential melastatin 7 (TRPM7) channels in rat hippocampal neurons in vitro. | 2011 Jun 10 |
|
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum. | 2013 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:09:10 GMT 2023
by
admin
on
Fri Dec 15 16:09:10 GMT 2023
|
Record UNII |
I38ZP9992A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
29365-4
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
17236-1
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
29364-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
57998-7
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
13474-2
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
29912-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2596-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2597-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
87469-3
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
2595-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
35252-6
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
57367-5
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
55938-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
24447-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
56956-6
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
42616-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
35249-2
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
32024-2
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
WHO-ATC |
A12CC01
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2594-0
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
32329-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
20872-8
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
14824-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
57368-3
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
2598-1
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
WHO-ATC |
B05XA11
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
54919-6
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2599-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LIVERTOX |
579
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
29911-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
44336-6
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
10880-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
23891-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
26746-8
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
50873-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
11554-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
58995-2
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
19124-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
74696-6
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
33950-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
27210-4
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
49007-8
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
87470-1
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
19123-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
26708-8
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2601-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
17235-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
9478-9
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
||
|
LOINC |
23892-3
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
2593-2
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
30536-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
21377-7
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
35250-0
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
18368-1
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
27122-1
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
CFR |
21 CFR 102.23
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
30922-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
25954-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
16172-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
18369-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
52911-5
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
17237-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
LOINC |
27255-9
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
||
|
DSLD |
82 (Number of products:11063)
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
I38ZP9992A
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
654
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
I38ZP9992A
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
5462224
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
100000091621
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
DB14513
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
7439-95-4
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
m6987
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | Merck Index | ||
|
231-104-6
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
DTXSID0049658
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
21 CFR 862.1495
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
C68264
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
Magnesium
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
D008274
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
25107
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
Magnesium (medical use)
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | |||
|
6574
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB14407MIG
Created by
admin on Fri Dec 15 16:09:10 GMT 2023 , Edited by admin on Fri Dec 15 16:09:10 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 16:09:11 GMT 2023 , Edited by admin on Fri Dec 15 16:09:11 GMT 2023
|
CONCEPT | Dietary Supplement |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
Nutritional value per 100 g (3.5 oz) - 21 mg (6%)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |